ANTX

AN2 Therapeutics Inc

3.55

Oct 23 • 3:59 PM ET -0.09 (-2.47%)

3.55

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: INSM SPRO ARMP AVIR ENTA COCP ACXP CRMD SNGX TRAW

| Held by: VTI IWM VXF VTWO IWN IWC BUSM DFAS GSSC AVSC

Scroll to Statements

Index	RUT
Market Cap	133.96M
Enterprise Value	55.57M
Income	-36.28M
Sales	0.00M
Book/sh	2.09
Cash/sh	2.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Mar 25, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.70
P/C	1.71
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.32
Current Ratio	14.32
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.07
EPS next Y	-0.80
EPS next Q	-0.20
EPS this Y	22.84%
EPS next Y	10.61%
EPS next 5Y	10.92%
EPS past 3/5Y	19.17% -8.39%
Sales past 3/5Y	- -
EPS Y/Y TTM	13.97%
Sales Y/Y TTM	-
EPS Q/Q	14.61%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	25.00% -

Insider Own	25.03%
Insider Trans	-0.60%
Inst Own	66.35%
Inst Trans	6.17%
ROA	-46.06%
ROE	-50.12%
ROIC	-47.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-18.86%
SMA50	-29.85%
SMA200	-11.16%
Trades

Shs Outstand	36.31M
Shs Float	28.29M
Short Float	8.81%
Short Ratio	10.00
Short Interest	2.49M
52W High	7.19 -50.63%
52W Low	1.00 255.00%
Volatility	6.33% 8.60%
ATR (14)	0.33
RSI (14)	29.82
Beta	-0.95
Rel Volume	0.50
Avg Volume	249.23K
Volume	124,442

Perf Week	5.03%
Perf Month	-27.40%
Perf Quarter	-27.99%
Perf Half Y	-18.20%
Perf YTD	211.40%
Perf Year	203.42%
Perf 3Y	-74.52%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	9.00
Prev Close	3.64
Price	3.55
Change %	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-26	Upgrade	Leerink Partners	Market Perform → Outperform	$9
Aug-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$5 → $1
Aug-09-24	Downgrade	Evercore ISI	In-line → Underperform
Jul-03-24	Upgrade	Leerink Partners	Market Perform → Outperform	$5
Apr-02-24	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$6
Feb-13-24	Downgrade	Leerink Partners	Outperform → Market Perform	$23 → $7
Feb-12-24	Downgrade	Oppenheimer	Outperform → Perform
Feb-12-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-12-24	Downgrade	Evercore ISI	Outperform → In-line	$25 → $7
Jan-04-24	Initiated	JMP Securities	Mkt Outperform	$30
Jul-18-22	Resumed	Oppenheimer	Outperform	$22

Show Previous Ratings

Oct-23-26 05:00PM	AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) (Business Wire)
Oct-21-26 07:00AM	AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms (Business Wire)
Oct-20-26 04:13PM	AN2 Therapeutics to Participate at Upcoming Investor Conferences (Business Wire) +5.64%
Sep-28-26 07:00AM	AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK (Business Wire)
Sep-16-26 05:33PM	AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) (Business Wire) -8.24%
06:00PM	Loading…
Aug-31-26 06:00PM	AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting (Business Wire)
Aug-24-26 07:00AM	AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer (Business Wire)
Aug-11-26 04:00PM	AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights (Business Wire) +6.98%
Jun-04-26 07:00AM	AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease (Business Wire)
May-21-26 07:00AM	AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference (Business Wire) +6.54%
May-11-26 04:01PM	AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights (Business Wire) +5.83% -9.53%
May-07-26 04:01PM	AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum (Business Wire)
Mar-31-26 07:00AM	AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease (Business Wire)
Mar-17-26 04:00PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire) +6.61% -7.60%
Mar-09-26 02:49PM	AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? (Benzinga) +84.21%
07:00AM	Loading…
07:00AM	AN2 Therapeutics Announces $40 Million Private Placement Financing (Business Wire)
Mar-03-26 04:00PM	AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) (Business Wire) +26.42%
Feb-17-26 07:00AM	AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference (Business Wire)
Jan-12-26 07:00AM	AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease (Business Wire) -12.31%
Jan-09-26 12:00PM	AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks)
Nov-12-25 04:01PM	AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Nov-10-25 07:00AM	AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) (Business Wire)
Nov-06-25 05:03PM	AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference (Business Wire)
Aug-12-25 04:01PM	AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire)
07:00AM	AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease (Business Wire)
Jul-23-25 07:00AM	AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease (Business Wire)
Jun-30-25 07:00AM	AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole (Business Wire)
May-29-25 07:00AM	AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference (Business Wire) +5.22%
May-13-25 04:01PM	AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire)
04:00PM	Loading…
May-01-25 04:00PM	AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline (Business Wire)
Apr-30-25 07:00AM	AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference (Business Wire)
Mar-25-25 04:00PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Mar-03-25 04:00PM	AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference (Business Wire)
Feb-24-25 07:00AM	AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease (Business Wire)
Feb-20-25 07:00AM	AN2 Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Jan-29-25 04:00PM	AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Nov-14-24 07:00AM	AN2 Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-13-24 04:00PM	AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline (Business Wire)
Oct-17-24 07:00AM	AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria (Business Wire)
Aug-28-24 04:00PM	AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-19-24 10:29AM	AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why (Zacks) +7.14%
Aug-16-24 07:00AM	AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan (Business Wire)
Aug-13-24 04:01PM	AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights (Business Wire) +5.83%
Aug-09-24 12:15PM	Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce (Benzinga) -60.98%
09:33AM	AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial (Pharmaceutical Technology)
Aug-08-24 04:30PM	AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease (Business Wire) +6.88%
Jul-03-24 09:50AM	Intuit initiated, Charter downgraded: Wall Street's top analyst calls (The Fly) +27.23%
May-21-24 09:35AM	Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround (Zacks)
May-14-24 10:55PM	ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Mar-28-24 11:53PM	ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +15.69%
04:10PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Feb-22-24 04:21AM	13 Best Falling Stocks To Buy Right Now (Insider Monkey)
Feb-12-24 10:03AM	AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) -74.50%
07:04AM	UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment (Reuters)
06:54AM	AN2 Therapeutics to pause lung disease study enrollment (Reuters)
06:45AM	AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease (Business Wire)
Jan-30-24 04:10PM	AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference (Business Wire)
Jan-12-24 03:02AM	AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares (GuruFocus.com)
Jan-10-24 08:50AM	Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why (Zacks)
Nov-09-23 04:05PM	AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights (Business Wire) -7.08%
Nov-06-23 08:50AM	AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
07:00AM	AN2 Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Oct-18-23 07:00AM	AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease (Business Wire)
Oct-11-23 12:01AM	AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023 (Business Wire)
Sep-27-23 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks)
Sep-26-23 07:00AM	AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria (Business Wire) +11.26%
Sep-13-23 07:00AM	AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease (Business Wire) -5.58%
Sep-11-23 09:40AM	Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-15-23 10:42PM	AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock (Business Wire) +7.06%
Aug-10-23 04:10PM	AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights (Business Wire)
Jun-14-23 08:55AM	Companies Like AN2 Therapeutics (NASDAQ:ANTX) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 04:10PM	AN2 Therapeutics to Present at Jefferies Healthcare Conference (Business Wire)
May-18-23 07:00AM	Eric Easom Spends US$54k On AN2 Therapeutics Stock \ (Simply Wall St.) -5.43%
May-11-23 04:10PM	AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights (Business Wire)
May-09-23 06:05AM	AN2 Therapeutics, Inc.'s (NASDAQ:ANTX) market cap dropped US$43m last week; individual investors who hold 33% were hit as were institutions (Simply Wall St.) -8.04%
May-01-23 07:00AM	AN2 Therapeutics to Present at JMP Securities Life Sciences Conference (Business Wire)
Mar-29-23 04:01PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (Business Wire)
Feb-28-23 04:10PM	AN2 Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Jan-31-23 04:10PM	AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference (Business Wire) +15.30%
Dec-04-22 08:40AM	AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-09-22 04:05PM	AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -7.43%
Nov-02-22 04:10PM	AN2 Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +10.07% +6.41%
Oct-19-22 08:00AM	AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022 (GlobeNewswire) -8.38%
Oct-06-22 07:00AM	AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease (GlobeNewswire)
Sep-29-22 07:00AM	NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million (GlobeNewswire) -7.21%
Aug-29-22 07:00AM	AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -10.18%
Aug-11-22 04:10PM	AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +6.42% +64.66%
Aug-08-22 11:42AM	What Type Of Shareholders Make Up AN2 Therapeutics, Inc.'s (NASDAQ:ANTX) Share Registry? (Simply Wall St.)
Jul-01-22 10:39AM	Bay Area's stream of new public companies has slowed to a weak trickle (American City Business Journals) +5.29%
Jun-29-22 07:00AM	AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease (GlobeNewswire)
Jun-27-22 09:19AM	We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate (Simply Wall St.)
May-10-22 04:10PM	AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +6.88% +6.81%
May-09-22 07:00AM	AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors (Business Wire) -19.66%
Apr-18-22 09:30AM	Here are the Bay Area's biggest startup exits of the first quarter (American City Business Journals) +5.49%
Mar-28-22 10:33AM	Only 9 Bay Area companies went public in this quarter. Here's how they did. (American City Business Journals)
Mar-25-22 04:40PM	AN2 Therapeutics Rises in First Day of Trading (Barrons.com)
03:06PM	RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15 (Benzinga)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Readnour Robin Shane	Director	Sep 09 '26	Sale	6.02	1,108	6,675	557,467	Sep 11 07:45 PM
Readnour Robin Shane	Director	Sep 08 '26	Sale	6.02	10,019	60,297	557,990	Sep 08 07:42 PM
Readnour Robin Shane	Director	Sep 03 '26	Sale	6.07	6,100	37,026	562,715	Sep 08 07:42 PM
Williams Sarah Joanne	Principal Accounting Officer	Sep 01 '26	Sale	5.53	272	1,504	66,311	Sep 04 04:25 PM
FitzPatrick Margaret M	Director	Sep 01 '26	Buy	5.53	2,098	11,602	10,708	Sep 02 06:43 PM
Readnour Robin Shane	Director	Aug 17 '26	Sale	6.01	35,402	212,702	565,592	Aug 19 05:58 PM
Readnour Robin Shane	Director	Aug 17 '26	Proposed Sale	6.01	1,012,000	6,080,268		Aug 17 04:24 PM
Eizen Joshua M	See Remarks	Jul 08 '26	Sale	4.17	5,945	24,803	206,554	Jul 10 06:15 PM
Williams Sarah Joanne	Principal Accounting Officer	May 29 '26	Sale	4.43	265	1,174	66,583	Jun 02 04:31 PM
Williams Sarah Joanne	Principal Accounting Officer	Mar 03 '26	Sale	1.06	327	347	66,848	Mar 05 06:55 PM
Day Lucy	Chief Financial Officer	Jan 06 '26	Sale	1.01	5,512	5,578	75,363	Jan 07 08:15 PM
Day Lucy	Chief Financial Officer	Jan 05 '26	Sale	1.00	3,295	3,305	80,875	Jan 07 08:15 PM
Prior Stephen David	Chief Strategy Officer	Jan 05 '26	Sale	1.00	3,604	3,615	61,944	Jan 07 08:15 PM
Prior Stephen David	Chief Strategy Officer	Jan 06 '26	Sale	1.01	2,858	2,892	59,086	Jan 07 08:15 PM
Chanda Sanjay	Chief Development Officer	Jan 06 '26	Sale	1.01	5,956	6,027	75,823	Jan 07 08:13 PM
Chanda Sanjay	Chief Development Officer	Jan 05 '26	Sale	1.00	3,295	3,305	81,779	Jan 07 08:13 PM
Eizen Joshua M	See Remarks	Jan 05 '26	Sale	1.00	17,923	17,948	159,430	Jan 07 08:12 PM
Eizen Joshua M	See Remarks	Jan 06 '26	Sale	1.01	6,931	7,014	152,499	Jan 07 08:12 PM
Eizen Joshua M	See Remarks	Nov 04 '25	Sale	1.14	2,819	3,214	177,353	Nov 06 06:12 PM
Prior Stephen David	Chief Strategy Officer	Nov 04 '25	Sale	1.14	765	872	65,548	Nov 06 06:11 PM

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley in 2017 and is headquartered in Menlo Park, CA.

Co-FounderMr. Eric E. Easom

Co-Founder & Independent DirectorMr. Joseph S. Zakrzewski

CFOMs. Lucy O. Day CPA

Chief Legal OfficerMr. Joshua M. Eizen J.D.

M.D.Dr. George Harrison Talbot FACP

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANTX

AN2 Therapeutics Inc

Upgrade your Finviz experience